Sentences with phrase «of oncology at»

Director of National Veterinary Laboratory Inc. and adjunct professor of oncology at University of Pennsylvania School of Veterinary Medicine

According to Margaret McEntee, DVM, a professor of oncology at Cornell University's College of Veterinary Medicine, approximately 85 percent of feline mammary cancers are lethally malignant adenocarcinomas.

But some years ago, Karin Sorenmo, a professor of oncology at the University of Pennsylvania School of Veterinary Medicine, realized that homeless shelter dogs could contribute in important ways to the understanding of breast cancer.

From 2001 - 2010 he was an Assistant Professor of Oncology at Cornell, where his research efforts were focused on clinical and translational projects involving cancer control and pharmacological validation of new agents.

«Some owners find it difficult to stop treatment,» says Karin Sorenmo, a professor of oncology at PennVet in Philadelphia, «but you can't think of it as giving up.

He's an assistant professor of oncology at Roswell Park Comprehensive Cancer Center, in Buffalo, N.Y.

The new findings «just further substantiate what we know about this class of drugs,» says Charles Loprinzi, MD, a professor of oncology at the Mayo Clinic, in Rochester, Minn..

«A lot of preparations have added so many things that they aren't releasing zinc properly,» said Dr. Ananda Prasad, professor in the department of oncology at Wayne State University School of Medicine in Detroit and an early pioneer of research into zinc as an essential mineral.

«Much to our surprise, the trial showed that patients receiving standard therapy compared to those receiving cetuximab with standard therapy had no difference in outcomes,» said study author Dr. Steven Alberts, a professor of oncology at the Mayo Clinic College of Medicine in Rochester, Minn. «It also indicates that disease in earlier stages may be different than diseases in later stages.»

«This study suggests that smokers who completely switch to e-cigarettes and stop smoking tobacco cigarettes may significantly reduce their exposure to many cancer - causing chemicals,» said lead author Maciej Goniewicz, an assistant professor of oncology at Roswell Park Cancer Institute in Buffalo, N.Y.

One of the selected landmark studies presented a breakthrough in gene editing by Todd Waldman, MD, PhD, a professor of oncology at the Georgetown Lombardi Comprehensive Cancer Center and director of the Georgetown MD / PhD Program.

August 16, 2016 — It has been more than two decades since Todd Waldman, MD, PhD, a professor of oncology at the Georgetown Lombardi Comprehensive Cancer Center and director of the Georgetown MD / PhD Program, published a study that led in part to earning his own MD / PhD degree at the Johns Hopkins School of Medicine.

«This study provides evidence that, in animals, a fathers» body weight at the time of conception affects both their daughters» body weight both at birth and in childhood as well as their risk of breast cancer later in life,» says the study's lead investigator, Sonia de Assis, PhD, an assistant professor in the department of oncology at Georgetown Lombardi.

The Phase I trial, funded by Cancer Research UK launched this June at the Institute of Oncology at St James's University Hospital in Leeds and Barts and The London's Experimental Cancer Medicine Centre in London.

«I am treating people today with pembrolizumab alone and seeing some impressive outcomes,» said Dr. Rosalyn Juergens, oncologist and site lead investigator at Hamilton Health Sciences» Juravinski Cancer Centre, and associate professor of oncology at McMaster University.

Currently, he is the Chief Scientific Officer of Oncology at Natera and the Founder and President of the Rare Genomics Institute.

These results support the current practice of extended trastuzumab treatment, according to Heikki Joensuu, MD, PhD, professor in the department of oncology at the Helsinki University Hospital and University of Helsinki in Finland, who presented the results.

Michelle Rudek, Pharm.D., Ph.D., is an associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Analytical Pharmacology Core for the Johns Hopkins Kimmel Cancer Center.

Dr. George Coukos is the director of the Department of Oncology at the University Hospitals of Canton Vaud (CHUV), the director of the service of developmental therapeutics, and the director of the Ludwig Centre at the University of Lausanne.

«What we see is an association between shorter periods of progression - free survival and overall survival in patients whose blood has higher levels of hypermethylated DNA, and we can see this very early on, after just four weeks of treatment,» says Sara Sukumar, Ph.D., professor of oncology at the Johns Hopkins University School of Medicine and member of the Kimmel Cancer Center, who developed the test with Johns Hopkins scientist Mary Jo Fackler, Ph.D., and others.

Raymond Niaura, PhD, the study's leader and senior author, is an adjunct professor of oncology at Georgetown Lombardi, and associate director for science of the Schroeder Institute for Tobacco Research and Policy Studies in Washington.

«There's a great need in cancer patients to be able to quickly and easily assess if a particular treatment is working in order to switch to another if it's not, thus avoiding wasted time, potential side effects and cost,» says Kala Visvanathan, M.D., M.H.S., professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, professor of oncology at the Johns Hopkins University School of Medicine and director of the Clinical Cancer Genetics Program at the Johns Hopkins Kimmel Cancer Center.

Todd Waldman is a Professor of Oncology at the Lombardi Comprehensive Cancer Center, Georgetown School of Medicine.

«It is difficult to dissuade children from smoking if one or both parents are heavily dependent on cigarettes,» says the study's lead investigator, Darren Mays, PhD, MPH, an assistant professor of oncology at Georgetown Lombardi.

Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Center.

Michael Carducci, MD, AEGON Professor of Prostate Cancer Research and professor of oncology at Johns Hopkins Kimmel Cancer Center, who is also chair of the Prostate Cancer Subcommittee within the Genitourinary Oncology Committee of ECOG - ACRIN agrees.

The study was led by Professor Angus Dalgleish, Professor of Oncology at St George's, University of London, working with independent UK - based biopharma Immodulon, owner of IMM - 101.

The more it's expressed only on cancer cells, the more targeted the therapy becomes,» says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medicine.

«One of the most painful things with my student loans was that one company would sell [my loan] to another and the rules would change, and you could be missing a payment or not know that you owe a payment,» says Vered Stearns, assistant professor of oncology at the Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins School of Medicine in Baltimore, Maryland.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

«We think it's probably because of getting involved with oral sex at an earlier age than earlier generations,» says Shanthi Marur, an assistant professor of oncology at Johns Hopkins Medicine's Upper Aerodigestive Cancer Program, who co-authored an August paper on the subject in The Lancet Oncology.

«Ovarian cancer treatments have not changed much in many decades, and this may be, in part, because we have been studying the wrong tissue of origin for these cancers,» says study leader Victor Velculescu, M.D., Ph.D., a professor of oncology at the Johns Hopkins Kimmel Cancer Center.

«Our findings have potential implications for autism and seizure disorders that currently aren't treatable — at least not by targeting GABA,» said Eisenstat, the senior author of the study and chair of the Department of Oncology at the U of A as well as professor in the departments of Pediatrics and Medical Genetics.

However, some of these cancers become resistant to the effects of radiation over time, according to Venu Raman, Ph.D., an associate professor of radiology and radiological science and of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.

In 1996, I relinquished an endowed chair of oncology at UNC Chapel Hill to become the scientific director of the Division of Clinical Sciences at the National Cancer Institute (NCI) near Washington, D.C..

«If your research is very risky and you haven't balanced it with other projects, your publication record can be at risk,» warns Klaus Hoeflich, a postdoctoral fellow in the department of oncology at Genentech.

The tumors» genomes were then analyzed for genetic mutations, or alterations in their DNA, by her team and that of Bert Vogelstein, M.D., professor of oncology at the Johns Hopkins University School of Medicine and the co-director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center.

In men whose prostate cancer spreads, doctors typically prescribe drugs that block testosterone production, but cancer cells eventually become resistant to this means of reducing the hormone, says Denmeade, a professor of oncology at the Johns Hopkins University School of Medicine.

Published in the journal Tobacco Control, the first study to model public health outcomes if cigarette smoking was replaced by e-cigarettes «supports a policy strategy that encourages replacing cigarette smoking with vaping to yield substantial life year gains,» says the study's lead author David Levy, PhD, professor of oncology at Georgetown Lombardi.

Norman Bleehan, professor of oncology at the University of Cambridge, says that more investigation is needed.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

«Finding the optimal conditions to avoid interfering with immune cells working to eradicate cancer while preventing graft rejection and GVHD is the holy grail of bone marrow transplant,» says Leo Luznik, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

According to Leena Hilakivi - Clarke, professor of oncology at Georgetown University School of Medicine, some women who gained more than 33 pounds during pregnancy had a significantly higher risk of breast cancer than mothers who kept their weight gain between 25 and 32 pounds.

Not exact matches

Also at GSK, she served as Vice President of Global Regulatory Affairs for Oncology, in addition to providing regulatory leadership on a number of innovation and operational excellence initiatives.

So, at the end of the day, are companies simply flocking to disease areas like oncology, and rare diseases — which have low chances of approval from phase one trials due to their complexities but carry high margins and high rewards if they do cross the regulatory finish line — at the expense of other conditions?

CEO Igor Barani, formerly a professor of radiation oncology at the University of California in San Francisco, says Enlitic's algorithms outperformed four radiologists in detecting and classifying lung nodules as benign or malignant.

Johnson & Johnson's cancer treatment Zytiga significantly cut the death risk for newly - diagnosed, advanced prostate cancer patients by 38 %, according to data unveiled at the ongoing American Society of Clinical Oncology (ASCO) annual meeting this weekend.

Now, we're getting the first look at that answer in data presented as part of the American Society of Clinical Oncology annual conference, which starts Friday.

«The shortage over many oncology drugs at that time was due to large manufacturers having quality problems and having to shut down,» said Valerie Jensen, associated director of the drug shortage staff at the FDA.